Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension

Blood Pressure

Volumn 7, Issue 1, 1998, Pages 31-37

  Stumpe, K O ^a   Haworth, D ^b   Hoglund, C ^c   Kerwin, L ^d   Martin, A ^e   Simon, T ^d   Masson, C ^e   Kassler Taub, K ^d   Osbakken, M ^d,f  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Surgery Layton Medical Centre   (United Kingdom)

^c Stockholm Heart Center   (Sweden)

^d BRISTOL MYERS SQUIBB   (United States)

^e Bristol Myers Squibb P ^*

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

adrenergic antagonist; Angiotensin II receptor antagonist; Atenolol; Hypertension; Irbesartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; HYDROCHLOROTHIAZIDE; IRBESARTAN; NIFEDIPINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 0031907449     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437547     Document Type: Article

References (22)

1. Kaplan NM. Treatment of hypertension: drug therapy. In: Kaplan NM, eds. Clinical hypertension. 6th ed. Baltimore, MD: Williams & Wilkins; 1994: 191-280.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13.
3. Stockwell DH, Madhavan S, Cohen H, Gibson G, Alderman MH. The determinants of hypertension awareness, treatment, and control in an insured population. Am J Public Health 1994; 84: 1768-74.
4. The Joint National Committee on Detection, Evaluation and Treatment of Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of high blood pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
5. Harper KJ, Forker AD. Antihypertensive therapy. Current issues and challenges. Postgrad Med 1992; 91: 163-93.
6. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987; 8: 69-74.
7. Laragh JH. Historical perspective on renin system blockade in the treatment of hypertension. Am J Hypertens 1992; 5: 207S-8S.
8. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221S-5S.
9. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis 1993; 22: 745-54.
10. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994; 12 (Suppl 2): S1-5.
11. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-34.
12. Burnier M, Buclin T, Biollaz J, Nussberger J, Waeber B, Brunner HR. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Kidney Int 1996; 49 (Suppl 55): S24-9.
13. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997 (in press).
14. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9.
15. Pool JL, Guthrie RM, Littlejohn T, et al. The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension [abstract]. Am J Hypertens 1996; 9: 152A.
16. Hagmann M, Burnier M, Nussberger J, et al. Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers [abstract]. Am J Hypertens 1994; 7: 13A.
17. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) [abstract]. J Hypertens 1994; 12: S92.
18. Martinez F, Schmitt F, Savoiu C, et al. Effect of SR 47436 (BMS 186295) on renal hemodynamics and on glomerular perm selectivity in healthy humans [abstract]. J Am Soc Nephrol 1994; 5: 607.
19. Pool JL, Guthrie RM, Littlejohn TW, III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1997 (in press).
20. Larochelle P, Flack JM, Hannah S, Smith S, Hwa J, Reeves RA. Irbesartan versus enalapril in severe hypertension [abstract]. Am J Hypertens 1997;10 (pt 2): 131A.
21. Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Osbakken M. Comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of hypertension [abstract]. J Hypertens 1997; 15 (Suppl 4): S117.
22. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214-26.